Poster Session F - Molecular Medicine 3.
Lakatos, Alexandra, MSc
Q6A6I1
Department of Physiology
+36305514464
lakatos.alexandra@phd.semmelweis.hu
Regulation of cellular ROS levels in cutaneous melanoma by MITF
Alexandra Lakatos1, Dorottya Pál2, Anna Sára Lengyel1, Petra Péter1, Botond Szabolcs1, Elmar Lutz1, Elisabeth M. Roider3, Akinori Kawakami3, Alicia McConnell4, Leonard Zon4, David E. Fisher5, Lajos V. Kemény6
1: HCEMM-SU Translational Dermatology Research Group, Tűzoltó street 37-47. 1094 Budapest, Hungary , Department of Physiology, Semmelweis University, Tűzoltó street 37-47. 1094 Budapest, Hungary , Department of Dermatology, Venerology and Dermatooncology, Semmelweis University, Mária street 41. 1085 Budapest, Hungary
2: HCEMM-SU Translational Dermatology Research Group, Tűzoltó street 37-47. 1094 Budapest, Hungary, Department of Physiology, Semmelweis University, Tűzoltó street 37-47. 1094 Budapest, Hungary, Department of Dermatology, Venerology and Dermatooncology, Semmelweis University, Mária street 41. 1085 Budapest, Hungary
3: Cutaneous Biology Research Center, Department of Dermatology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA
4: Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts and the Howard Hughes Medical Institute, Boston, USA
5: Cutaneous Biology Research Center, Department of Dermatology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
6: HCEMM-SU Translational Dermatology Research Group, Tűzoltó street 37-47. 1094 Budapest, Hungary , Department of Physiology, Semmelweis University, Tűzoltó street 37-47. 1094 Budapest, Hungary , Department of Dermatology, Venerology and Dermatooncology, Semmelweis University, Mária street 41. 1085 Budapest, Hungary, Cutaneous Biology Research Center, Department of Dermatology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA
Poszter
Poster Session F - Molecular Medicine 3.
Hungarian
Molecular Medicine
Introductions: Microphthalmia-associated transcription factor (MITF) is crucial in melanocyte development, function, and melanoma pathogenesis. MITF amplification is common in melanoma and is associated with resistance to targeted therapies. The production of eumelanin is thought to shield the melanocytes and keratinocytes from UV damage by buffering the accumulation of UV-induced reactive oxygen species (ROS) during pigment production. We hypothesized that, besides controlling the synthesis of the antioxidant eumelanin, MITF might promote ROS clearance by contributing to the regulation of cellular ROS homeostasis.
Aims: We aim to demonstrate that MITF regulates a global antioxidant program that increases the survival of melanoma cell lines by protecting the cells from reactive oxygen species (ROS)-induced damage.
Methods: Pathway analyses using publically available datasets were made with DAVID and Cytoscape. Cells were transfected with a siRNA delivery system. Cytosolic ROS levels were measured by DCFDA fluorescent dye using flow cytometry. Cell viability was measured with trypan blue. Zebrafish were injected with MiniCoopR MITF overexpression plasmid. Zebrafish older than 15 days were euthanized by rapid chilling via submersion in ice water for 30 minutes. 8-oxoG was detected by mass spectrometry
Results: Pathways analyses indicate that MITF might regulate a transcriptional redox program in melanoma. Functional studies demonstrate the role of MITF and its target genes in reducing cytosolic and mitochondrial ROS. In vivo experiments using a zebrafish melanoma model showed that MITF decreases ROS-mediated DNA damage. Some MITF target genes, such as IDH1 and NNT, are regulated through direct MITF binding to canonical E-BOX sequences proximal to their promoters. Our data suggests that MITF is a major driver of the cellular antioxidant state
Conclusion: MITF directly (and indirectly) regulates multiple genes that collectively support the survival of melanoma cells from ROS
Funding: L.V.K. is a recipient of the János Bolyai Research Scholarship of the Hungarian Academy of Sciences and is supported by the Hungarian National Research, Development, and Innovation Office (OTKA FK138696) grant, a STIA-KFI grant from Semmelweis University. The project has received funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 739593
Semmelweis University
Lajos Vince Kemény MD, PhD
I do not give consent to the publication of my abstract on the website of the congress.
Szabad
elfogadva
poszter
nem rendelkezett róla
7350
15:00
15:03